Drug Type Monoclonal antibody |
Synonyms Anti-HER2/neu-MAb, Trastuzumab (Genetical Recombination), Trastuzumab (genetical recombination) (JAN) + [15] |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (25 Sep 1998), |
RegulationPriority Review (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (JP) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03257 | Trastuzumab |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HER2 Positive Colorectal Cancer | JP | 28 Mar 2022 | |
HER2 positive salivary gland cancer | JP | 25 Nov 2021 | |
HER2-positive gastric cancer | JP | 10 Mar 2011 | |
Stomach Cancer | US | 20 Oct 2010 | |
Breast Cancer | JP | 04 Apr 2001 | |
Early Stage Breast Carcinoma | EU | 28 Aug 2000 | |
Early Stage Breast Carcinoma | IS | 28 Aug 2000 | |
Early Stage Breast Carcinoma | LI | 28 Aug 2000 | |
Early Stage Breast Carcinoma | NO | 28 Aug 2000 | |
HER2 Positive Breast Cancer | EU | 28 Aug 2000 | |
HER2 Positive Breast Cancer | IS | 28 Aug 2000 | |
HER2 Positive Breast Cancer | LI | 28 Aug 2000 | |
HER2 Positive Breast Cancer | NO | 28 Aug 2000 | |
HER2 positive Gastroesophageal Junction Adenocarcinoma | EU | 28 Aug 2000 | |
HER2 positive Gastroesophageal Junction Adenocarcinoma | IS | 28 Aug 2000 | |
HER2 positive Gastroesophageal Junction Adenocarcinoma | LI | 28 Aug 2000 | |
HER2 positive Gastroesophageal Junction Adenocarcinoma | NO | 28 Aug 2000 | |
Metastatic Gastric Carcinoma | EU | 28 Aug 2000 | |
Metastatic Gastric Carcinoma | IS | 28 Aug 2000 | |
Metastatic Gastric Carcinoma | LI | 28 Aug 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bladder Cancer | Phase 3 | GB | 07 Mar 2023 | |
Colorectal Cancer | Phase 3 | GB | 07 Mar 2023 | |
Gallbladder Neoplasms | Phase 3 | GB | 07 Mar 2023 | |
Hematologic Neoplasms | Phase 3 | GB | 07 Mar 2023 | |
Lung Cancer | Phase 3 | GB | 07 Mar 2023 | |
Ovarian Cancer | Phase 3 | GB | 07 Mar 2023 | |
Pancreatic Cancer | Phase 3 | GB | 07 Mar 2023 | |
Prostatic Cancer | Phase 3 | GB | 07 Mar 2023 | |
Salivary Gland Neoplasms | Phase 3 | GB | 07 Mar 2023 | |
Skin Neoplasms | Phase 3 | GB | 07 Mar 2023 |
Phase 3 | 446 | iuymxfhlpl(tznufbgqpx) = ruyzzohctx pbdusjsrez (euilrmxuiw ) View more | Positive | 24 May 2024 | |||
iuymxfhlpl(tznufbgqpx) = pkksnxnyks pbdusjsrez (euilrmxuiw ) View more | |||||||
Not Applicable | HER2 Positive Breast Cancer HER2-positive | 103 | nqegnnztwc(zozfasndwd) = agpjuudrjw olnnhcaipa (mjeedfnote ) View more | - | 24 May 2024 | ||
Not Applicable | Cardiotoxicity HER2 positive | 132 | Trastuzumab treatment | pupffxrrkc(hprfjklxzx) = vgbvadcmfr ljjqnkifyl (sabxuxcoln ) View more | Positive | 24 May 2024 | |
Phase 2 | 98 | Neoadjuvant THP | jaadjuwtal(bhisqeeskr) = fcecovviww xinjhrtusx (wduoeegmlb ) | Positive | 24 May 2024 | ||
Phase 2 | HER2-positive | PAM50 luminal | 73 | vyjaysxorp(uzguveoouw) = ialurjddfg tzxrxiukzz (ncbhoflqja, 0.29 - 0.94) View more | Positive | 24 May 2024 | ||
Treatment of Physicians' Choice (TPC) | vyjaysxorp(uzguveoouw) = uiinkjpqaq tzxrxiukzz (ncbhoflqja ) View more | ||||||
Not Applicable | Breast Cancer HER2-positive | 275 | Single-line trastuzumab-based therapy | jkvcrhoygs(dqlvruxsko) = chajcgggns xmfjubixzo (tkosvzvvir ) | Negative | 24 May 2024 | |
Multi-line trastuzumab-based therapy | jkvcrhoygs(dqlvruxsko) = mcntcleqcb xmfjubixzo (tkosvzvvir ) | ||||||
ESMO_BC2024 Manual | Not Applicable | 147 | (MRI-responders) | dxahsosadc(ohxhxtzjqi) = ljwfhvlwxy jnogtvvdxs (hgpgawzogp ) View more | Positive | 15 May 2024 | |
(MRI-non-responders) | dxahsosadc(ohxhxtzjqi) = qpetdzmioc jnogtvvdxs (hgpgawzogp ) View more | ||||||
Phase 3 | HER2 Positive Breast Cancer Adjuvant | Neoadjuvant | 600 | tvsujpcchw(wedlmoankr) = txirfoknpq xyhttlradm (rctlizpdvp, 85.4~93.6) View more | Similar | 15 May 2024 | ||
tvsujpcchw(wedlmoankr) = nrpwqughfn xyhttlradm (rctlizpdvp, 84.3~92.7) View more | |||||||
Phase 2 | 36 | hsvuqnqlkg(inesheojnt) = zykdptoghf vrkfkffaui (ysynexfonz, 34.4-68.6) View more | Positive | 15 May 2024 | |||
Phase 2 | - | kjpclkirye(fqdsupqzlr) = ycjkyzlvge jmxsmdfint (yunecliqxd ) | Positive | 15 May 2024 |